Santen Pharmaceutical Co., Ltd.
4536
주식 순위
#4330
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
주가
$11.35
마지막 동기화: 2026-10-16
시가총액
$3.65B
변동 (1일)
1.55%
변동 (1년)
-0.91%
국가
JP
거래 Santen Pharmaceutical Co., Ltd. (4536)
카테고리
Healthcare
의 시가총액 Santen Pharmaceutical Co., Ltd.(4536)
시가총액: $3.65B
October 2026 기준으로 Santen Pharmaceutical Co., Ltd.의 시가총액은 $3.65B입니다. 이는 당사 데이터에 따르면 Santen Pharmaceutical Co., Ltd.이 세계에서 4330th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2010부터 2026까지 Santen Pharmaceutical Co., Ltd.의 시가총액 기록
